Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2019 Sep 11

PMID 31501711

Citations 35

Authors

Samaneh Arab

Jamshid Hadjati

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has been introduced into cancer treatment methods, but different problems have restricted the efficacy of these protocols in clinical trials such as the presence of various immunomodulatory factors in the tumor microenvironment. Adenosine is an immunosuppressive metabolite produced by the tumor to promote growth, invasion, metastasis, and immune evasion. Many studies about adenosine and its metabolism in cancer have heightened interest in pursuing this treatment approach. It seems that targeting the adenosine pathway in combination with immunotherapy may lead to efficient antitumor response. In this review, we provide information on the roles of both adenosine and CD73 in the immune system and tumor development. We also describe recent studies about combination therapy with both purinergic inhibitors and other immunotherapeutic methods.

Citing Articles

The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.

Simoes J, Braga G, Fontana M, Assmann C, Bagatini M Brain Sci. 2025; 14(12.

PMID: 39766485 PMC: 11674974. DOI: 10.3390/brainsci14121286.

CD73 promotes non-small cell lung cancer metastasis by regulating Axl signaling independent of GAS6.

Zhu J, Du W, Zeng Y, Liu T, Li J, Wang A Proc Natl Acad Sci U S A. 2024; 121(43):e2404709121.

PMID: 39423241 PMC: 11513981. DOI: 10.1073/pnas.2404709121.

Mathematical modeling of hypoxia and adenosine to explore tumor escape mechanisms in DC-based immunotherapy.

Ghiyabi E, Arabameri A, Charmi M Sci Rep. 2024; 14(1):11387.

PMID: 38762567 PMC: 11102449. DOI: 10.1038/s41598-024-62209-6.

Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.

Hamed A, Ghareeb D, Mohamed T, Hamed M, Nofal M, Gaber M BMC Complement Med Ther. 2023; 23(1):384.

PMID: 37891562 PMC: 10604858. DOI: 10.1186/s12906-023-04212-4.

Immune Features of Tumor Microenvironment: A Genetic Spotlight.

Asadi M, Zarredar H, Zafari V, Soleimani Z, Saeedi H, Caner A Cell Biochem Biophys. 2023; 82(1):107-118.

PMID: 37870699 DOI: 10.1007/s12013-023-01192-7.

References

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

Goepfert C, Sundberg C, Sevigny J, Enjyoji K, Hoshi T, Csizmadia E . Disordered cellular migration and angiogenesis in cd39-null mice. Circulation. 2001; 104(25):3109-15. DOI: 10.1161/hc5001.100663. View

Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A . Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 2002; 101(10):3985-90. DOI: 10.1182/blood-2002-07-2113. View

Cronstein B, Levin R, Philips M, Hirschhorn R, Abramson S, Weissmann G . Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992; 148(7):2201-6. View

Sullivan G, Lee D, Ross W, DiVietro J, Lappas C, Lawrence M . Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol. 2003; 75(1):127-34. DOI: 10.1189/jlb.0603300. View

Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J . Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2003; 103(4):1391-7. DOI: 10.1182/blood-2003-06-1959. View

Hasko G, Cronstein B . Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2003; 25(1):33-9. DOI: 10.1016/j.it.2003.11.003. View

Turtle C, Hart D . Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets. 2004; 5(1):17-39. DOI: 10.2174/1389450043490640. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

10.

Sitkovsky M, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C . Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004; 22:657-82. DOI: 10.1146/annurev.immunol.22.012703.104731. View

11.

Taylor P, Martinez-Pomares L, Stacey M, Lin H, Brown G, Gordon S . Macrophage receptors and immune recognition. Annu Rev Immunol. 2005; 23:901-44. DOI: 10.1146/annurev.immunol.23.021704.115816. View

12.

Raskovalova T, Huang X, Sitkovsky M, Zacharia L, Jackson E, Gorelik E . Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol. 2005; 175(7):4383-91. DOI: 10.4049/jimmunol.175.7.4383. View

13.

Kreckler L, Wan T, Ge Z, Auchampach J . Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2005; 317(1):172-80. DOI: 10.1124/jpet.105.096016. View

14.

Jacobson K, Gao Z . Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):247-64. PMC: 3463109. DOI: 10.1038/nrd1983. View

15.

Kondo T, Nakazawa T, Murata S, Katoh R . Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology. 2006; 48(5):612-4. DOI: 10.1111/j.1365-2559.2005.02277.x. View

16.

Sadej R, Spychala J, Skladanowski A . Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 2006; 16(3):213-22. DOI: 10.1097/01.cmr.0000215030.69823.11. View

17.

Bours M, Swennen E, Di Virgilio F, Cronstein B, Dagnelie P . Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006; 112(2):358-404. DOI: 10.1016/j.pharmthera.2005.04.013. View

18.

Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M . A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103(35):13132-7. PMC: 1559765. DOI: 10.1073/pnas.0605251103. View

19.

Fredholm B . Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007; 14(7):1315-23. DOI: 10.1038/sj.cdd.4402132. View

20.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View